

**PARP inhibitor increases chemosensitivity by upregulating miR-664b-5p in
BRCA1-mutated triple-negative breast cancer**

Wei Song¹, Lin Tang², Yumei Xu¹, Jing Xu³, Wenwen Zhang², Hui Xie⁴, Shui Wang⁴, Xiaoxiang Guan^{1,2}

¹Department of Medical Oncology, Jinling Hospital, Southern Medical University, Guangzhou, 510515, China.


²Department of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing, 210002, China.

³Department of Medical Oncology, Jinling Hospital, Nanjing Medical University, Nanjing, 210002, China.

⁴Department of Breast Surgery, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, China.


Correspondence and requests for materials should be addressed to X. G. (email: xguan@nju.edu.cn) or S. W. (email: ws0801@hotmail.com).

S1



Supplementary Fig. 1. The non-BRCA1-mutated TNBC cell line MDA-MB-231 were treated with CBP (10 μ M) plus GEM (100 nM) combined with or without olaparib (10 μ M) for the indicated times, and then, the cell viability was determined with an MTT assay. The results show data from six independent experiments expressed as the mean \pm SD. $p < 0.05$.

S2



Supplementary Fig. 2. The expression of miR-664b-5p in non-BRCA1-mutated TNBC cell line MDA-MB-231 after treated with CBP plus GEM combined with or without olaparib was measured with qRT-PCR.